IGF2BP1 and liver cancer: Taken together, the above results suggest that ASNS may be a reliable target gene of METTL3/IGF2BP1, and METTL3/m6A(ASNS)/IGF2BP1 axis may serve as a novel promising therapeutic target for liver cancer, which deserved to be investigated in depth.